Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Betaine-homocysteine S-methyltransferase 2 (BHMT2) is a zinc-dependent metalloenzyme that catalyzes the transfer of a methyl group from S-methylmethionine (SMM, also known as vitamin U, often derived from plant-based foods) to homocysteine, generating methionine[1][2][5]. Unlike its close homolog BHMT, which uses betaine as a methyl donor, BHMT2 is specific for SMM and is unable to utilize betaine as a substrate[1][2]. The enzyme plays a role in methionine biosynthesis as part of the broader one-carbon metabolic pathway, which is essential for methyl group transfer and regulation of homocysteine, a metabolite associated with cardiovascular and other diseases when dysregulated[3][5]. BHMT2’s tissue expression and physiological details are less well characterized than BHMT, but it is known to be present in the liver[5]. Disease associations for BHMT2 are inferred based on its role in homocysteine/methionine metabolism, with possible links to cardiovascular and metabolic diseases; however, unlike BHMT, direct drug targeting, interacting drugs, or use as a clinical biomarker are not established[5].\n\nKey characteristics:\n- BHMT2 is part of the methyltransferase (specifically, S-methylmethionine-homocysteine methyltransferase) family and shares structural elements with the broader Pfam 02574 family of enzymes[1].\n- It displays high specificity for SMM and does not use betaine, with differences in substrate binding sites explaining selectivity compared to BHMT[1].\n- BHMT2 is a zinc metalloenzyme and may oligomerize, with possible regulatory or evolutionary interactions with BHMT[1].\n- Though it can catalyze the methylation of homocysteine using S-adenosylmethionine (AdoMet) in vitro, its primary physiological function appears centered on SMM[1][2].\n- No known drugs directly target BHMT2, and no safety or toxicology concerns are reported in the literature[5].\n- No clinically established biomarkers or mechanisms of action for drugs targeting BHMT2 are known according to current public biomedical resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Betaine-homocysteine S-methyltransferase 2 (BHMT2).